Although a phase II study of the anti–TGF-β antibody GC1008 in mesothelioma was prematurely terminated despite preliminary evidence of activity [168], dual blockade of TGF-β and PD-1/PD-L1 is under evaluation in various solid tumors. This evidence concerns the gene CD274 and mesothelioma.